Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/28/2012

zures and C. difficile-associated diarrhea (CDAD); for full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Disclosure Notice Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2012, our belief that Vancocin meets the requirements for, and thus received, three years of exclusivity, ability to continue to successfully commercialize our products in the United States and Europe, our ability to complete manufacturing scale up procedures, and receive regulatory approvals in the time frames anticipated, our ability to manufacture specified quantities of Cinryze utilizing the existing manufacturing process or additional manufacturing procedures; our ability to pursue regulatory approvals in additional territories; and our ability to conduct additional studies in the timeframes we anticipate.

Our actual results may vary depending on a variety of factors, including:

  • the development of competitive generic versions of oral Vancocin;
  • our ability to receive regulatory approval for the use of Cinryze for additional indications and formulations and in additional territories in the
    '/>"/>

  • SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. ViroPharma to Present at Three September Healthcare Conferences
    2. ViroPharma to Present at Three October Healthcare Conferences
    3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
    4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
    5. ViroPharma to Present at Three November Healthcare Conferences
    6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
    7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
    8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
    9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
    10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
    11. ViroPharma to Present at Two June Healthcare Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/24/2014)... (PRWEB) November 24, 2014 2014 ... Dihydrazide Industry is a professional and in-depth research ... Adipic Dihydrazide information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
    (Date:11/24/2014)...  Spherix Incorporated (Nasdaq: SPEX ) -- an ... and monetization of intellectual property, today provided an ... No. 3:13-cv-03494-M and  Spherix v. Uniden Corporation et ... United States District Court for the Northern District ... On November 21, 2014 the Markman hearing ...
    (Date:11/23/2014)... 2014 Apiscent Labs, a privately ... chemical ingredients to the global pharmaceutical and flavor ... new website, Apiscent.com. , The Apiscent.com homepage welcomes ... design, easy navigation, rotating images and content focused ... out. , The company’s work in ...
    (Date:11/22/2014)... During his lifetime Richard L. Sharp was a ... with great people and take risks to achieve success. ... at his extraordinarily courageous attitude when taking on challenges. ... with his death impending—that’s how he continued looking for ... take his life. , Carrying on Sharp’s relentless dream ...
    Breaking Biology Technology:Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3
    ... of chemistry in the College of Science, has been ... and engineers in the early stages of their independent ... and Engineers, or PECASE. "I am very honored ... a rich environment for accomplishing nanoscience research using state-of-the-art ...
    ... ... ... var shortURL = ""; BitlyCB.alertResponse = ... the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) ...
    ... ... ... var shortURL = ""; BitlyCB.alertResponse = ... the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) ...
    Cached Biology Technology:LSU’s Jayne Garno receives early career award from President 2Atrium Innovations Announces Third Quarter Financial Results of 2010 2Atrium Innovations Announces Third Quarter Financial Results of 2010 3Atrium Innovations Announces Third Quarter Financial Results of 2010 4Atrium Innovations Announces Third Quarter Financial Results of 2010 5Atrium Innovations Announces Third Quarter Financial Results of 2010 6Atrium Innovations Announces Third Quarter Financial Results of 2010 7Atrium Innovations Announces Third Quarter Financial Results of 2010 8Atrium Innovations Announces Third Quarter Financial Results of 2010 9Atrium Innovations Announces Third Quarter Financial Results of 2010 10Atrium Innovations Announces Third Quarter Financial Results of 2010 11Atrium Innovations Announces Third Quarter Financial Results of 2010 12Atrium Innovations Announces Third Quarter Financial Results of 2010 13Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 2Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 3Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 4Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 5Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 6Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 7Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 8
    (Date:11/3/2014)... LOS ANGELES , Nov. 3, 2014 /PRNewswire/ ... California -based life sciences company focused on ... eTNS system for the treatment of neurological ... Institute of Industrial Property has issued a Notice ... The patent application is co-owned by NeuroSigma and ...
    (Date:11/2/2014)... month,s issue of Physics World , James Dacey ... "valley of death" to take their innovations from the ... the gruelling challenge facing all start-up companies as they ... physicists because of two main factors: physics-based inventions are ... often turn out to be a lot more complicated ...
    (Date:11/2/2014)... child, it was fascinating to put a flashlight up ... the hand. Washington University in St. Louis engineers are ... body,s tissues to improve imaging of cancerous tissues and ... the Gene K. Beare Distinguished Professor of Biomedical Engineering ... applying a novel time-reversal technology that allows researchers to ...
    Breaking Biology News(10 mins):NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2Improving imaging of cancerous tissues by reversing time 2
    ... signals in response to vibrations within the inner ear, could ... One way to do this could be with gene therapy ... at Emory University School of Medicine have shown that introducing ... can induce the formation of extra sensory hair cells. ...
    ... , This press release is available in ... (KIT) will be granted more,autonomy and far more freedom ... KIT Further Development,Act, as a result of which KIT ... its employees in the future. In,addition, KIT will have ...
    ... work of a Marshall University biology professor, the nation,s ... West Virginia will be preserved for future generations. ... grant from the National Science Foundation to re-curate and ... housed in the university,s College of Science. Her colleague ...
    Cached Biology News:Gene therapy for hearing loss: Potential and limitations 2More freedom of discretion for KIT 2Biology professor secures grant to save West Virginia's primary natural history collection 2
    ... The IDS 25-Hydroxy Vitamin D kit ... quantitative determination of 25-hydroxyvitamin D (25-OH ... human serum or plasma. Our patented ... of solvent precipitation and centrifugation and ...
    ... kit is a competitive enzymeimmunoassay (EIA) for ... or rat serum or plasma. Corticosterone is ... rats and mice, and in most non-mammalian ... Most mammals produce both corticosterone and cortisol, ...
    Mouse monoclonal [BC-4] to Aggrecan xxPEN ( Abpromise for all tested applications). entrezGeneID: 176 SwissProtID: P16112...
    Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
    Biology Products: